Beyfortus 50 mg (Nirsevimab SOLUTION) 50 MG

BEYFORTUS 50 MG is a solution containing nirsevimab, used for respiratory syncytial virus (RSV) prevention. This intramuscular solution is manufactured by Sanofi Pasteur Limited in Canada.

Strength

50 MG

Manufacturer / TM Owner

SANOFI PASTEUR LIMITED

Select Quantity

Pack/s

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

First Name

Last Name

Phone

Delivery Country

Delivery PostCode/Zipcode

Select Your Profile

I have read and agree to the terms & conditions, including the privacy policy, return policy, and usage terms as applicable to this request.

Indications & Clinical Uses

BEYFORTUS 50 MG is primarily used for the prevention of respiratory syncytial virus (RSV) infections. RSV is a common respiratory virus that can cause severe illness, particularly in infants and young children. This medication is designed to provide protection against RSV, helping to reduce the risk of infection and its associated complications.

Side Effects

The effects of BEYFORTUS 50 MG are focused on preventing RSV infections. By administering this solution intramuscularly, it helps the body build immunity against the virus, potentially reducing the severity and frequency of RSV-related illnesses.

Precautions & Warnings

BEYFORTUS 50 MG should be handled with care, following the instructions provided by healthcare professionals. It is important to store the solution properly and ensure it is administered correctly to achieve the desired preventive effects. Always consult with a healthcare provider before use.

Avoid Interactions

BEYFORTUS 50 MG may interact with other medications or substances, so it is important to inform your healthcare provider about all medications you are taking. This includes over-the-counter drugs, supplements, and any other treatments. Alcohol and certain foods may also affect the effectiveness of the solution.

Frequently Asked Questions

BEYFORTUS 50 MG is used for the prevention of respiratory syncytial virus (RSV) infections, particularly in infants and young children.

BEYFORTUS 50 MG is administered intramuscularly, typically by a healthcare professional.

The common effects of BEYFORTUS 50 MG include building immunity against RSV, potentially reducing the severity and frequency of RSV-related illnesses.

Yes, it is important to handle BEYFORTUS 50 MG with care, store it properly, and follow the administration instructions provided by healthcare professionals.

Yes, BEYFORTUS 50 MG may interact with other medications, so it is important to inform your healthcare provider about all medications you are taking.

Editorial & Trust Signals

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical wholesaler & exporter

Last updated: 17 Jun 2026

References

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.